|
 Company: NOVARTIS, ISTANBUL TURKEY
Entry Submitted by: EFFECT PUBLIC RELATIONS
Company Description: Market leader in sales, Novartis Turkey functions in pharmaceutical and consumer health industries. Offering treatment in diabetes, cardiology, respiratory, oncology, dermatology, rheumatology, CNS and ophthalmology Novartis Turkey has around 2000 employees working in production, marketing and clinical research working in 5 production factories.
Nomination Category: Company & Office Categories
Nomination Sub Category: Best Corporate Social Responsibility Program in the Middle East and Africa
Nomination Title: NOVARTIS HEALTH WAGON PROJECT, TURKEY
1. Tell the story about what this nominated company achieved in the past year (up to 500 words). Focus on specific accomplishments, and relate these accomplishments to past performance or industry norms. Be sure to mention obstacles overcome, innovations or discoveries made, and outcomes:
The Health Wagon Project of Novartis Turkey is an extensive training and
public awareness campaign on chronic diseases where Novartis is offering
treatment; cardiology, respiratory, oncology, dermatology, rheumatology, CNS
and ophthalmology.
The project is conducted in 20 different cities around Turkey on main railway
routes from November 2005 till August 2006.
?A Train Wagon is redecorated as a health unit with examination rooms and a
meeting room for educational purposes.
?Two physicians and one nurse worked in this project permanently.
?Training sessions were held about diseases - hypertension, diabetes, hyper-
lipidemia, asthma, alzheimer, osteoporosis, IBS, cancer, epilepsy, Parkinson’s
disease, acromegaly, depression, fungus, thalassemia- their symptoms,
precautions and the maintenance of health. Besides the permanent responsible
doctor of the wagon, training was given by the local KoL’s or family
physicians.
?In parallel to the trainings, the other activity of the Health Wagon was
metabolic syndrome screening conducted on the “Cardio-Metabolic Risk Factors
in Turkey” under the supervision of the Metabolic Syndrome Association. It is
the first report on ethiological factors of coronary artery disease among
adults researching dislipidemia prevelance and relation of dislipidemia with
insulin resistance; postprandial glycemia and kidney functions in Turkey.
Objectives:
?To increase public awareness on Novartis
?To increase public awareness on chronic diseases.
?Screening
?Strengthen reputation of Novartis among stakeholders.
?CME need of GP’s and Specialists
Promotional Activities:
?An opening ceremony was organized in each city with the participation of the
local government, NGO and health office representatives, physicians,
academicians and the media.
?Posters and brochures were distributed around the city before wagon arrives
the city. Billboards, radio programs, telephone/sms messages, public
announcements also supported the communication of the Project.
?Internet site under Novartis Turkey web site was updated daily to communicate
the activities in the Novartis Health Wagon with photos (www.novartis.com.tr)
Results:
Novartis Health Wagon project was a transformational, highest impact project.
?5000 people were trained throughout 9 months.
?1317 people screened for their metabolic risk factors.
?Metabolic Syndrome Association and Ministry of Health approaches Novartis as
a partner.
?The coverage in local media was considerably high.
10 days after the program, for each city a tele-survey is conducted with the
participants to evaluate the success of trainings.
?Effectiveness of the trainings is measured by the behavior change at the end
of the training 1:
o91% found the trainings beneficial
o44% visited a doctor later on
o25% changed their nourishment style or started diet
o85% shared the knowledge with the family
o37% started exercising
o10% quitted smoking
?Awareness of the public about Novartis:
Recall of the Novartis Health Wagon Project is 99% among those who
participated the training.
Novartis is the 5th, with 2.3%, among the first recalled pharma companies,
which are providing products for chronic diseases
Critical Success Factors:
Project increased the improvement of public awareness on wide range of
diseases and to make them take action related to their health problems. 5000
patients have been given quality and effective education. The project reached
success through full cooperation with important stakeholders. The project
also supported the development of the Report of the “Cardio Metabolic Risk
Factors in Turkey”.
Key learnings:
?This is the first and only project implemented in various cities, achieving
the contribution of all the key stakeholders at the same time, namely Ministry
of Health and Health Offices of the Ministry in the cities, National Security
Offices, Governors, Municipalities, Medical Universities, Metabolic Syndrome
Society, local media and field force.
?The coverage in local media is considerably high.
2. List hyperlinks to any online news stories, press releases, or other documents that support the claims made in the section above. IMPORTANT: Begin each link with http://, and enclose each link in square brackets; for example, [http://www.youraddress.com]:
More information regarding the project can be found at :
http://www.novartis.com.tr/vagon
http://thestevies.com/IBA07Attachments/NovartisHealthWagonProject.doc
http://thestevies.com/IBA07Attachments/NovartisHealthWagonProject.pdf
3. Provide a brief (up to 100 words) biography about the leader of this nominated company:
Dr. Aylin Gürer
Graduated from Hacettepe University, completed her MBA at Bilkent University
and received her PhD at Istanbul University, Labor Economics and Industry
Relations Department in 2001. Gurer worked at United Nations (Ankara) as
International Projects Coordinator She joined Novartis in 1997 and she was
appointed as the Corporate Relations and Communications Director in 2005.
Ekin Erim
Graduated from Hacettepe University in 1996, Erim worked at Nurus, Bayindir,
Yasamkent, Total Lighting and DBR. After working at Saatchi & Saatchi Erim
joined Novartis Turkey as Corporate Communication Associate in 2005. She was
appointed as the Pharma Communication Manager in 2007.
|
